Obama FDA Head that Allowed Opioid Crisis to Increase Confirmed to Lead the FDA Again as COVID Shots Set to Join Annual Flu Shots in Windfall for Big Pharma

Apparently Robert Califf did such a good job of helping Big Pharma shield themselves from any liabilities due to the opioid crisis that destroyed the lives of so many Americans while he was head of the FDA under President Obama, that he is being brought back to lead the FDA again to help Big Pharma continue growing in record profits and sales as they get ready to expand the market for the COVID-19 gene-altering shots by having Americans get vaccinated every year, along with the already profitable flu shots. While he was approved to lead the FDA by the Senate in an overwhelming vote of support with an 89-4 Senate vote on his confirmation in 2016, this time around he barely survived the confirmation vote which was 50-46, facing bi-partisan opposition to his confirmation. Yesterday, Project Veritas released a video recording with "FDA Executive Officer, Christopher Cole" who was caught on camera admitting that the FDA was planning making the COVID shots an annual requirement, in a financial windfall for the Pfizer and other COVID-19 vaccine manufacturers. He also confirmed that the FDA works for the pharmaceutical companies who pay the FDA "hundreds of millions of dollars a year to hire and keep the reviewers to approve their products."

The FDA now officially belongs to Big Pharma

It is hard to believe only four senators opposed the confirmation of Robert Califf, who was approved [recently] as the next FDA commissioner. Califf, chancellor of clinical and translational research at Duke University until recently, received money from 23 drug companies including the giants like Johnson & Johnson, Lilly, Merck, Schering Plough and GSK according to a disclosure statement on the website of Duke Clinical Research Institute. Not merely receiving research funds, Califf also served as a high level Pharma officer, say press reports. Medscape, the medical website, discloses that Califf “served as a director, officer, partner, employee, advisor, consultant or trustee for Genentech.” Portola Pharmaceuticals says Califf served on its board of directors until leaving for the FDA. In disclosure information for a 2013 article in Circulation, Califf also lists financial links to Gambro, Regeneron, Gilead, AstraZeneca, Roche and other companies and equity positions in four medical companies. Gilead is the maker of the $1000-a-pill hepatitis C drug AlterNet recently wrote about. This is FDA commissioner material?